← Back to Search

CAR T-cell Therapy

KITE-718 for Solid Tumors

Phase 1
Waitlist Available
Research Sponsored by Kite, A Gilead Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to year 2 for solid tumor participants and up to year 5 for multiple myeloma participants
Awards & highlights

Study Summary

This trial is testing a new cancer treatment to see if it is safe and effective.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to year 2 for solid tumor participants and up to year 5 for multiple myeloma participants
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to year 2 for solid tumor participants and up to year 5 for multiple myeloma participants for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Phase 1A - Percentage of Participants Experiencing Adverse Events Defined as Dose-Limiting Toxicities
Phase 1B - Efficacy: Objective Response Rate (ORR)
Secondary outcome measures
Duration of Response (DOR)
Levels of MAGE-A3/A6 TCR-transduced T Cells in Blood
Overall Survival
+4 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: KITE-718Experimental Treatment4 Interventions
Phase 1A: Participants will receive cyclophosphamide and fludarabine conditioning chemotherapy followed by the investigational treatment, KITE-718. Phase 1 B: Participants will receive cyclophosphamide and fludarabine conditioning chemotherapy followed by the investigational treatment, KITE-718, at a dose selected based on Phase 1A.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Cyclophosphamide
1995
Completed Phase 3
~3770
Fludarabine
2012
Completed Phase 3
~1100

Find a Location

Who is running the clinical trial?

Kite, A Gilead CompanyLead Sponsor
43 Previous Clinical Trials
3,640 Total Patients Enrolled
Kite Study DirectorStudy DirectorKite, A Gilead Company
28 Previous Clinical Trials
2,998 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who else is applying?

What state do they live in?
Arizona
How old are they?
65+
What site did they apply to?
Banner MD Anderson Cancer Center
USC/Norris Comprehensive Cancer Center
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
clinicaltrials.govStudy
Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Adults With Advanced Cancers
2017. "Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Adults With Advanced Cancers". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03139370.
~2 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top